+86-28-82633987
Product name: Celosin I
Synonym name:
Catalogue No.: BP4205
Cas No.: 1807732-38-2
Formula: C53H82O24
Mol Weight: 1103.22
Botanical Source:
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Description:
Celosin H, celosin I, and celosin J could be used as chemical markers for the quality control of C. argentea seeds. Celosin I exhibited significant hepatoprotective effect on carbon tetrachloride-induced and N,N-dimethylformamide-induced hepatotoxicity in mice.
References:
Nat Prod Res. 2013 Aug;27(15):1353-60.
Novel triterpenoid saponins from the seeds of Celosia argentea L.
METHODS AND RESULTS:
Two new triterpenoid saponins Celosin I (1) and Celosin II (2) were isolated from the seeds of Celosia argentea L. (Amaranthaceae). The structures of the two new compounds were elucidated based on chemical analysis and spectral methods (IR, 1-D and 2-D NMR, ESI-MS, HR-ESI-MS).
CONCLUSIONS:
They exhibited significant hepatoprotective effect on carbon tetrachloride-induced and N,N-dimethylformamide-induced hepatotoxicity in mice.
HPLC of Celosin I
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
388.0400
1.3182
-1.4264
.6030
.5203
.2553
Low
79.5750
6.9320
Yes
No
Yes
No
No
No
0.0
Yes
No
No
No
Celosin I is a novel triterpene saponin natural product, first isolated and identified from the seeds of the traditional medicinal plant Celosia argentea L. As an important active ingredient in Qingxiang seeds, Cyanyanin I can serve not only as a chemical marker for quality control of broad bean seeds but also attracts widespread attention in the pharmacological community due to its remarkable bioactivity. In recent years, vinantin I has demonstrated good pharmacological potential in anti-inflammatory and hepatoprotective fields, especially in models of liver injury induced by carbon tetrachloride (CCl_4) and N,N-dimethylformamide (DMF). This paper aims to systematically review the chemical structure, physicochemical properties, plant origin, and extraction methods of Cylindrin I, deeply explore its pharmacological activity and mechanism of action, evaluate its druggability and pharmacokinetic characteristics, and anticipate its clinical application potential, providing theoretical basis and research directions for natural product pharmacology and new drug development.
Cyanangin I belongs to the triterpene saponin class of compounds with a complex molecular formula and a molecular weight of 1103.2150. Its structural core is a typical triterpene backbone, connecting multiple glycosyl residues to form a polysaccharide structure, which gives it high polarity and water solubility. The LogP value of vinyanin I is 1.3182, indicating moderate hydrophobicity, which facilitates distribution and penetration of cell membranes within organisms. Its polar surface area (TPSA) reaches as high as 388.04 Ų, reflecting the presence of a large number of polar groups on the molecular surface, enhancing its water solubility (0.6030), but simultaneously limiting its ability to cross the blood-brain barrier, which has low permeability. Cyanin I does not have hERG channel inhibitory activity, indicating a low risk of cardiotoxicity, and the Ames test result is 0.0, indicating no significant genotoxicity risk.
From a chemical structure perspective, the triterpene backbone of vinyin I provides its bioactive basis, while the glycosyl component may affect its bioavailability and targeting. Polar functional groups such as hydroxyl and carboxyl groups in the structure provide various possible hydrogen bonding and electrostatic interaction sites for binding to target proteins.
Celosia I mainly comes from the seeds of Celosia argentea L. Qingxiang is a traditional Chinese medicinal herb widely distributed in tropical and subtropical regions, and its seeds contain abundant triterpene saponin compounds. The extraction of vincinin I is usually done using solvent extraction combined with chromatography separation. The specific steps include:
In recent years, new green extraction technologies such as ultrasound-assisted extraction and microwave-assisted extraction have also been tried for the extraction of vincinin I, improving extraction efficiency and purity, and reducing solvent usage and energy consumption.
Pharmacological activity research on vinanin I has mainly focused on its anti-inflammatory and hepatoprotective effects. Multiple in vivo and in vitro experiments have shown that vinyanin I has significant protective effects against various liver injury models and demonstrates good activity in regulating inflammatory responses.
The carbon tetrachloride (CCl_4) induced mouse liver injury model is a classic model for evaluating hepatoprotective drugs. Studies have found that vincinin I can significantly reduce CCl_4-induced hepatocyte necrosis and inflammatory infiltration, inhibit the elevation of malondialdehyde (MDA) levels in liver tissue, enhance superoxide dismutase (SOD) activity, and alleviate oxidative stress damage. Additionally, vinyl glycoside I can improve liver function indicators such as serum ALT and AST levels, demonstrating good liver-protective effects.
Similarly, in the N,N-dimethylformamide (DMF)-induced hepatotoxicity model, vinyl glycoside I also demonstrated anti-liver injury effects, reducing hepatocyte inflammation and fibrosis processes, and promoting liver tissue repair.
Cyanin I demonstrated significant anti-inflammatory activity across various inflammation models. Its mechanism of action involves regulation of multiple classic inflammatory signaling pathways, reducing the expression of pro-inflammatory cytokines such as TNF-α and IL-6, and inhibiting the activity of inflammatory mediator synthase PTGS2 (COX-2) and induced nitric oxide synthase NOS2, thereby alleviating inflammatory responses.
Additionally, vininin I regulates the inflammation-related ion channels TRPV1 and TRPA1, potentially exerting anti-inflammatory and analgesic effects by modulating neuroinflammation and pain transmission. Its inhibition of the inflammasome-related protein CASP1 (caspase-1) also suggests its potential role in regulating inflammatory cell apoptosis and cytokine maturation.
The pharmacological effects of vincinin I are mainly realized through multi-target and multi-pathway synergistic actions, involving multiple mechanisms such as immune regulation, antioxidant activity, and signal transduction.
Cyaninin I significantly affects the IL-6/STAT3 signaling pathway. IL-6, as a key pro-inflammatory cytokine, promotes inflammatory responses and cell survival by activating the STAT3 transcription factor. Glycoside I can inhibit IL-6 expression and STAT3 phosphorylation activation, blocking inflammatory signal transmission and reducing inflammatory responses.
At the same time, vininin I inhibits activation of the NFKB1 (NF-κB) signaling pathway, reduces transcription expression of pro-inflammatory genes, lowers the production of inflammatory mediators such as TNF-α and PTGS2, and exerts anti-inflammatory effects.
The inhibitory effect of cyanoside I on CASP1 suggests it may regulate inflammasome activity, reduce the maturation and release of pro-inflammatory cytokines such as IL-1β, and alleviate apoptosis and tissue damage of inflammatory cells.
The regulatory effect of vininin I on TRPV1 and TRPA1 may alleviate inflammation-related pain by inhibiting the influx of calcium ions mediated by these channels, blocking neuroinflammatory signaling.
Cyanin I enhances antioxidant enzyme activity, reduces oxidative stress products, protects hepatocytes from free radical damage, and maintains intracellular redox balance.
The druggability evaluation of vinanin I showed good safety and potential drug development value.
Currently, pharmacokinetic research on vininin I is relatively limited. Preliminary data indicate that its metabolism is stable in the body, mainly processed by hepatic metabolic enzyme systems, and its excretion pathway still needs further clarification. In the future, systematic pharmacokinetic and toxicological studies are needed to evaluate its absorption, distribution, metabolism, and excretion (ADME) characteristics, providing a basis for clinical application.
As a natural compound with multi-target anti-inflammatory and hepatoprotective activities, Cyanangin I has promising clinical development potential. Its application prospects are broad in liver diseases, especially acute and chronic liver injury, drug-induced hepatitis, and liver fibrosis. At the same time, the properties of vincinin I in regulating inflammatory signaling pathways make its potential therapeutic value in autoimmune diseases, inflammatory pain, and metabolic syndrome-related inflammation worthy further exploration.
Future research directions include:
As a natural triterpenoid saponin with a clear origin and unique structure, vinyl glycoside I demonstrates significant anti-inflammatory and hepatoprotective effects. Its multi-target regulation of inflammatory signaling pathways and antioxidant mechanisms provides a solid foundation for its pharmacological effects. Druggability evaluation shows that it has good safety and potential clinical value. In the future, with deeper analysis of pharmacological mechanisms and advances in drug development technology, peaniside I is expected to become a novel natural drug for treating liver diseases and inflammation-related conditions, contributing significantly to the field of natural product pharmacology and new drug development.
Shenshuai
Wenjing
Hedandan
